Sources

Complete reference list

Every source cited anywhere on this site, numbered. Bracketed numbers on the topic pages point here.

Complete Reference List (403 Sources)

All sources are peer-reviewed systematic reviews, meta-analyses, randomized controlled trials, or major clinical studies from 2016-2026. Emphasis on 2024-2026 publications.

Understanding OLT [1-9]

Conservative Management [10-14]

Hyaluronic Acid / PRP [15-19]

Bone Marrow Stimulation / Microfracture [20-28]

BioCartilage / Scaffolds / AMIC [29-34]

OATS / Autograft [35-40]

Osteochondral Allograft [41-45]

Juvenile Cartilage / DeNovo [46-47]

Subchondralplasty [48-53]

Fusion vs. Replacement [54-62]

Additional 2024-2025 Sources [63-74]

OATS/Autograft Extended [75-78]

[75] OATS Systematic Review Update (2024)
[76] Novel Arthroscopic OATS Technique (2024)
[77] Single-Plug OATS Technique (2024)
[78] Ipsilateral Talus as Donor Site (2024)

Allograft Extended [79-82]

[79] Fresh OCA Outcomes Review (2024)
[80] Fresh Talar Allograft Outcomes (2025)
[81] Bulk vs Shell Allograft Comparison (2024)
[82] Revision Allograft Outcomes (2024)

DeNovo/Subchondralplasty Extended [83-85]

Fusion/TAA Extended [86-89]

[86] TAA vs Arthrodesis - JBJS (2024)
[87] 3D-Printed Custom TAA Implants (2024)
[88] National Registry TAA Data (2025)
[89] Arthrodesis Techniques Update (2024)

ACI/MACI [90-91]

[90] ACI 20-Year Follow-Up (2024)
[91] MACI Systematic Review (2024)

Stem Cell / Regenerative [92-94]

Shockwave Therapy (ESWT) [95-98]

PEMF Therapy [99-102]

[99] PEMF for Bone and Cartilage: Review (2025)
[100] PEMF for Knee OA: In Vitro Study (2024)
[101] PEMF and Sirt1/NF-κB Pathway (2025)
[102] NASA PEMF Technology Development

Physical Therapy & Rehabilitation [103-106]

Lifestyle & BMI [107]

[107] BMI Influence on OLT Outcomes: German Registry (2025)

Nutritional Supplements [108-111]

[108] Glucosamine/Chondroitin Systematic Review (2025)
[109] Cartilage-Supporting Supplements RCT (2025)
[110] NIH/NCCIH: Glucosamine and Chondroitin
[111] Collagen Derivatives Meta-Analysis (2024)

Gene Therapy [112-114]

Return to Sport [115-119]

[115] Return to Sports After OLT: 2,347 Cases (2019)
[116] OLT in Athletes: Up-to-Date Review (2017)
[117] Return to Sports After BMDCT (2016)
[118] Sports After OCA Transplantation (2024)
[119] Pediatric Microfracture Return to Sport (2024)

Imaging & Staging [120-123]

Risk Factors [124-127]

[124] Smoking and AOT Outcomes: 5-Year Study (2025)
[125] Medial OLT in CLAI vs Ankle Varus (2025)
[126] Concomitant OLT in Ankle Instability (2024)
[127] CLAI Effects on OLT Outcomes (2024)

Surgical Approaches [128-131]

[128] DGOU 2024 OLT Recommendations
[129] MMO in German Cartilage Registry (2024)
[130] MMO vs AMO Comparison (2025)
[131] Medial Talar Dome Lesions Outcomes (2024)

Metal Resurfacing [132-133]

Revision Surgery [134-135]

[134] Realignment for Failed OAT (2024)
[135] Repeat Arthroscopy and Microfracture (2024)

Cryopreserved Allografts [136-138]

3D Bioprinting & Future [139-140]

Psychological Factors [141-142]

Platelet-Rich Fibrin [143-144]

[143] PRF for High-Grade OLT (2024)
[144] PRP with AOT for OLT + CLAI (2025)

Osteoperiosteal Revision / TOPIC / AOPT [145-147]

[145] TOPIC 5-Year Prospective Outcomes (2024)
[146] AOPT vs AOCT Comparison: 65 vs 65 Patients (2025)
[147] Return to Sport After TOPIC (2026)

Revision Surgery Extended [148-149]

Metal Resurfacing Extended [155-156]

Alignment & Instability Extended [157]

[157] Alignment, Instability, and OLT Surgical Planning (2025)

Total Talar Replacement [158-215]

2026 Updates [169-180]

HA Injection Optimization [181-189]

Revision Allograft [190-196]

Activity-Specific Evidence [197-204]

Bracing & Orthotics [205-209]

Clinical Trials [210-212]

July 2026 Research Log [216-228]

Added by the weekly literature sweep of July 20–26, 2026. Publication dates verified against PubMed, Europe PMC, Crossref, or ClinicalTrials.gov records.

July 27, 2026 Research Log [229-237]

Added by the weekly literature sweep of July 27, 2026, covering items dated July 18–27 that were not captured in the previous sweep. Publication and posting dates verified against Europe PMC, Crossref, ClinicalTrials.gov, openFDA, or the publisher's own record — not from search-result snippets. Two entries are older publications that had not previously been recorded; their true dates are given rather than the date they surfaced.

July 28, 2026 Research Log [238-246]

Added by the weekly literature sweep of July 28, 2026, covering items dated July 21–28 that were not captured in the two previous sweeps. Publication dates verified against Europe PMC, Crossref, ClinicalTrials.gov, or the publisher's own deposited record — not from search-result snippets. References [244]–[246] are older sources added this week: the two ankle HA trials correct a false claim previously made on this page, and the FDA safety communication had never been recorded.

July 29, 2026 Research Log [247-271]

Added by the sweep of July 29, 2026, covering items dated July 26–29 not captured in the three previous sweeps. Dates verified against Crossref created, ClinicalTrials.gov API fields, Europe PMC, SEC filing dates, or a registry's own record — never from a search-result snippet. References [251]–[259] and [262]–[264] are older sources added this week because they had never been recorded: [251] and [252] materially affect the long-term decision, [253] names a treatment option not previously on this page, and [262]–[264] come from the AAOS guideline's own evidence base, which was read in full for the first time this week — correcting what this page previously said about the hyaluronic acid literature.

July 30, 2026 Research Log [272-289]

Added by the sweep of July 30, 2026, covering items dated July 29–30 not captured in the four previous sweeps. The peer-reviewed window was almost empty; most of what follows is regulatory, payer or access material verified from primary sources — SEC filing exhibits, FDA device databases, published payer guidelines, statutory text and institutions' own pages. References [283]–[285] are older clinical papers added because they are candidate evidence exhibits for an insurance appeal, and [287] is added because it is the most revision-heavy talar allograft series in the United States.

July 31, 2026 Research Log [290-300]

Added by the sweep of July 31, 2026. The peer-reviewed window was again nearly empty of ankle content, so the value this week came from three other places: the 2018 international consensus proceedings, which were retrieved in full open access from a university repository after the 2026 successor proved genuinely closed, and which have never appeared on this page despite being the most directly on-point documents in it; a set of older papers surfaced by re-indexing and verified to be months rather than days old; and a patient registry that fits this lesion's criteria. References [290]–[294] are the 2018 consensus set; [295]–[299] are clinical papers backfilled from earlier in 2025–2026.

August 1, 2026 Research Log [301-317]

Added by the sweep of August 1, 2026. The week's structural discovery is that the international consensus proceedings series is ten papers, not the five recorded last week — the five that were missing were retrieved in full open access and contain the highest-graded evidence on this site, including a Grade A1 statement that bears directly on the trial's bone-marrow-stimulation arm. A near-miss is recorded rather than buried: this sweep independently “rediscovered” the failed-talar-allograft revision literature and the Bugbee/Scripps recommendation and reported both as new. They were already on this site — see [190]–[196] and the revision allograft topic page — and those duplicates were removed before publication. References [301]–[306] and [315] are consensus papers; [307] and [312]–[313] and [317] are provider and access verifications; [308]–[310] are industry findings; [311], [314] and [316] are clinical papers new to this site.

August 3, 2026 Research Log [318-340]

Added by the sweep of August 3, 2026. Very little was published this week — the single in-window item is a correspondence exchange whose text cannot be retrieved. The value is in what chasing it surfaced: a 2026 Level 1 randomised trial and two phenotype-exact cohort studies [318]–[321], none previously held here, which together say the bone marrow stimulation arm is the wrong operation for a 15 mm cystic revision lesion. [322]–[326] are FDA adverse-event and tissue-safety records from the MAUDE pass the August 1 log left open. [327]–[328] and [339] are surgeon verifications; [329]–[332] are statutes and payer records that change how a second opinion can be obtained; [333]–[338] and [340] are access, registry and trial verifications.

[442] Law KHK, Koh JH, Seow D — “Autologous Bone Grafting for the Treatment of Osteochondral Lesion of the Talus: A Systematic Review and Meta-Analysis” — Journal of the American Podiatric Medical Association, Crossref-created 2026-08-26, DOI 10.3390/japma116050058, PMID 42776815 (indexed 2026-09-24 — the watch landed after 29 days; MEDLINE, print issue J Am Podiatr Med Assoc 116(5):58, cover date 2026-08-26; the published abstract matches the Crossref version this entry was written from). Added 2026-08-26, in-window; abstract read in full from Crossref. PRISMA systematic review, PubMed/Embase/Cochrane, JBJS level-of-evidence and Modified Coleman quality grading, fixed/random-effects by heterogeneity: eleven studies of autologous bone grafting for OLT. Pooled: AOFAS 56.0 ± 10.1 → 88.7 ± 5.7; VAS 6.5 → 1.7; overall complication rate 3.82% (CI 0.05–10.92), one DVT the only debilitating complication. Authors’ proposal: bone grafting “should be considered as the first line of treatment for lesion sizes >150 mm²”, positioned as the alternative to osteochondral transplantation for large lesions; longer follow-up explicitly called for. Discounts: pools the same retrospective single-center series the site carries individually (see [439] for what that design does to cartilage-repair numbers), heterogeneous graft sources and techniques, short follow-ups. Carried to topic 26: the first pooled estimate for the bone-graft family, and a citable first-line argument for the large cystic-lesion territory this ankle occupies

[443] Nakamura S, Uezono N, Shimanoe K, Ide T, Tsutsumi S, Saho S, Dogomori M, Fujimoto Y, Ijuin T, Taniguchi N — “Association Between Talar Morphology and Subchondral Bone Sclerosis in the Medial Gutter of Patients With Chronic Lateral Ankle Instability” — Foot & Ankle Orthopaedics, Crossref-created 2026-08-26, DOI 10.1177/24730114261471905, PMID 42662097 (indexed 2026-08-29). Added 2026-08-26, in-window; structured abstract read in full from Crossref. Kagoshima University: 27 CLAI patients (34 ankles) before arthroscopic ligament repair vs 30 controls (34 feet), quantitative CT of volumetric BMD across 8 medial-gutter subregions normalized to fibular BMD, plus talar morphology (anterior opening angle, anterior/posterior width, trochlea length). Medial-gutter BMD ratios significantly higher in CLAI, concentrated anteriorly; CLAI ankles had talar tilt 11.6° vs 4.6° and anterior drawer 7.2 vs 5.1 mm; BMD elevation correlated with larger anterior opening angle (r = 0.48–0.60) and smaller posterior width (r = −0.41 to −0.49, FDR-corrected), with no such associations in controls. Level III, retrospective, cross-sectional, adaptation marker not outcome. Carried to topic 28: mechanism-level support for the stability-first rule — anteromedial subchondral remodeling is measurable at the pre-arthritic stage of instability, in the exact region this site’s lesion story lives in

[444] University of Twente news release — “New treatment for ankle cartilage damage under development” (AMPLANK project) — published 2026-08-14, surfaced by the 2026-08-26 news sweep (out-of-window by twelve days; dedup zero sitewide, carried as a first mention rather than re-reported news). Institutional announcement, not peer-reviewed. AMPLANK: a patient-specific 3D-printed titanium implant for ankle cartilage damage, developed by the University of Twente (Athena Jalalian) with Radboudumc (Dennis Janssen), the Sint Maartenskliniek, a Fraunhofer innovation platform at UT and industrial partners; custom-fit to each ankle, designed for the joint’s confined space without removing healthy bone, aimed at “young and active patients”. Stage: preclinical prototype development — planned computer simulation, then anatomical fit testing, with surgical-procedure development alongside; no registered trial, no clinical timeline, no funding details disclosed. Carried to topic 19 as a watch item: the second patient-specific focal talar resurfacing effort in the world, targeted at the exact gap that page documents (Episealer single-size, Europe-only, corporate limbo). Watch for a first-in-human registration or the project’s first peer-reviewed paper

[448] Nanochon press release — “Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™” — published 2026-08-14, surfaced by the 2026-08-29 news sweep (out-of-window by fifteen days; dedup zero sitewide, carried as a first mention). Company announcement, not peer-reviewed. Chondrograft: a 3D-printed porous nanocomposite synthetic implant for focal articular cartilage defects — off-the-shelf, designed for immediate joint loading, no autologous cell harvest; first-in-human study cleared by Panamá’s Ministry of Health (a Health Canada clinical clearance also stated), to run at The Panama Clinic, in knees. No registry entry located at carry time; no human outcomes exist. Carried to topic 22 as a watch item: the first off-the-shelf load-bearing printed-scaffold entrant of its class to reach a human trial — the single-surgery profile that MACI-class therapies lack. Watch for the trial’s registration and any ankle extension. Update 2026-09-01: the registrations existed all along and the watch closes — the 09-01 registry sweep’s sponsor search found NCT07542184 (Panama FIH early-feasibility study, The Panama Clinic, 5 patients, RECRUITING, actual start 2026-07-30, first posted 2026-04-21) and NCT07249489 (Canadian sibling, UBC Vancouver + Toronto, 10 patients, RECRUITING, first posted 2025-11-25); both knee-only (ages 22–60, focal cartilage lesions), both mini-arthrotomy or arthroscopic implantation, primary completions late 2027. The 08-29 “no registry entry located” line was a search failure, not an absence — the Canadian record predated the carry by nine months. New watch: first outcomes, and any ankle extension. Update 2026-10-01: the device’s first peer-reviewed preclinical data published — a six-goat paired pilot in Cartilage with a positive 16-week histology signal and a permanent-remnant/foreign-body trade-off; carried as [493]